Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.
Markets
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
Fed-and-SEC desk, TradeNews USA (2026-09-21): Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030 The weight-loss-drug manufacturer failed to excite investors hoping for a… Primary source: original at MarketWatch (marketwatch.com).